Abstract
Objective: To analyze the Routine Assessment of Patient Index Data 3 (RAPID3), a patient-reported, composite index, designed initially for feasibility in clinical care. RAPID3 was developed in rheumatoid arthritis, but has been found useful in many rheumatic diseases. We analyzed RAPID3 in patients with psoriatic arthritis (PsA). Methods: Post hoc analyses were performed on 2 independent data sets, the Tight Control of Psoriatic Arthritis (TICOPA) clinical trial, and the Long-Term Outcome in Psoriatic Arthritis Study (LOPAS II), an observational cohort. RAPID3 (range 0–30) is the total of three 0–10 scores for the Health Assessment Questionnaire disability index (recalculated from 0–3), pain visual analog scale (VAS), and global VAS. RAPID3 scores were compared to the Psoriatic Arthritis Disease Activity Score (PASDAS), the Disease Activity in Psoriatic Arthritis (DAPSA), and other available clinical measures, according to Spearman's correlation coefficients, standardized response mean, SEM, smallest detectible difference, minimally important difference (in patients who improved), and receiver operating characteristic curves. RAPID3 remission was compared to criteria for both standard minimal disease activity (MDA) and very low disease activity (VLDA). Results: RAPID3 was correlated significantly with PASDAS in TICOPA (r = 0.79, P < 0.01) and with DAPSA in LOPAS II (ρ = 0.59, P < 0.01), and with most other measures in both data sets. RAPID3 discriminated between tight control and standard care in TICOPA at 48 weeks at levels comparable to DAPSA and the PASDAS (P < 0.01). RAPID3 remission discriminated treatment groups in TICOPA intermediate between MDA and VLDA criteria. Conclusion: RAPID3 appears comparably informative to PASDAS and DAPSA in PsA, with greater feasibility for routine clinical care.
| Original language | English |
|---|---|
| Pages (from-to) | 1198-1205 |
| Number of pages | 8 |
| Journal | Arthritis Care and Research |
| Volume | 70 |
| Issue number | 8 |
| Early online date | 7 Nov 2017 |
| DOIs | |
| Publication status | Published - 1 Aug 2018 |
Fingerprint
Keywords
- Journal Article
ASJC Scopus subject areas
- Rheumatology
Cite this
Value of the Routine Assessment of Patient Index Data 3 in Patients With Psoriatic Arthritis : Results From a Tight-Control Clinical Trial and an Observational Cohort. / Coates, Laura C.; Tillett, William; Shaddick, Gavin; Pincus, Theodore; Kavanaugh, Arthur; Helliwell, Philip S.
In: Arthritis Care and Research, Vol. 70, No. 8, 01.08.2018, p. 1198-1205.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Value of the Routine Assessment of Patient Index Data 3 in Patients With Psoriatic Arthritis
T2 - Results From a Tight-Control Clinical Trial and an Observational Cohort
AU - Coates, Laura C.
AU - Tillett, William
AU - Shaddick, Gavin
AU - Pincus, Theodore
AU - Kavanaugh, Arthur
AU - Helliwell, Philip S.
N1 - © 2017, American College of Rheumatology.
PY - 2018/8/1
Y1 - 2018/8/1
N2 - Objective: To analyze the Routine Assessment of Patient Index Data 3 (RAPID3), a patient-reported, composite index, designed initially for feasibility in clinical care. RAPID3 was developed in rheumatoid arthritis, but has been found useful in many rheumatic diseases. We analyzed RAPID3 in patients with psoriatic arthritis (PsA). Methods: Post hoc analyses were performed on 2 independent data sets, the Tight Control of Psoriatic Arthritis (TICOPA) clinical trial, and the Long-Term Outcome in Psoriatic Arthritis Study (LOPAS II), an observational cohort. RAPID3 (range 0–30) is the total of three 0–10 scores for the Health Assessment Questionnaire disability index (recalculated from 0–3), pain visual analog scale (VAS), and global VAS. RAPID3 scores were compared to the Psoriatic Arthritis Disease Activity Score (PASDAS), the Disease Activity in Psoriatic Arthritis (DAPSA), and other available clinical measures, according to Spearman's correlation coefficients, standardized response mean, SEM, smallest detectible difference, minimally important difference (in patients who improved), and receiver operating characteristic curves. RAPID3 remission was compared to criteria for both standard minimal disease activity (MDA) and very low disease activity (VLDA). Results: RAPID3 was correlated significantly with PASDAS in TICOPA (r = 0.79, P < 0.01) and with DAPSA in LOPAS II (ρ = 0.59, P < 0.01), and with most other measures in both data sets. RAPID3 discriminated between tight control and standard care in TICOPA at 48 weeks at levels comparable to DAPSA and the PASDAS (P < 0.01). RAPID3 remission discriminated treatment groups in TICOPA intermediate between MDA and VLDA criteria. Conclusion: RAPID3 appears comparably informative to PASDAS and DAPSA in PsA, with greater feasibility for routine clinical care.
AB - Objective: To analyze the Routine Assessment of Patient Index Data 3 (RAPID3), a patient-reported, composite index, designed initially for feasibility in clinical care. RAPID3 was developed in rheumatoid arthritis, but has been found useful in many rheumatic diseases. We analyzed RAPID3 in patients with psoriatic arthritis (PsA). Methods: Post hoc analyses were performed on 2 independent data sets, the Tight Control of Psoriatic Arthritis (TICOPA) clinical trial, and the Long-Term Outcome in Psoriatic Arthritis Study (LOPAS II), an observational cohort. RAPID3 (range 0–30) is the total of three 0–10 scores for the Health Assessment Questionnaire disability index (recalculated from 0–3), pain visual analog scale (VAS), and global VAS. RAPID3 scores were compared to the Psoriatic Arthritis Disease Activity Score (PASDAS), the Disease Activity in Psoriatic Arthritis (DAPSA), and other available clinical measures, according to Spearman's correlation coefficients, standardized response mean, SEM, smallest detectible difference, minimally important difference (in patients who improved), and receiver operating characteristic curves. RAPID3 remission was compared to criteria for both standard minimal disease activity (MDA) and very low disease activity (VLDA). Results: RAPID3 was correlated significantly with PASDAS in TICOPA (r = 0.79, P < 0.01) and with DAPSA in LOPAS II (ρ = 0.59, P < 0.01), and with most other measures in both data sets. RAPID3 discriminated between tight control and standard care in TICOPA at 48 weeks at levels comparable to DAPSA and the PASDAS (P < 0.01). RAPID3 remission discriminated treatment groups in TICOPA intermediate between MDA and VLDA criteria. Conclusion: RAPID3 appears comparably informative to PASDAS and DAPSA in PsA, with greater feasibility for routine clinical care.
KW - Journal Article
UR - http://www.scopus.com/inward/record.url?scp=85050637034&partnerID=8YFLogxK
U2 - 10.1002/acr.23460
DO - 10.1002/acr.23460
M3 - Article
VL - 70
SP - 1198
EP - 1205
JO - Arthritis Care and Research
JF - Arthritis Care and Research
SN - 2151-464X
IS - 8
ER -